| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 07/25/2002 | WO2001090091A8 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 07/25/2002 | WO2001078701A3 Method and compositions for preventing hormone induced adverse effects |
| 07/25/2002 | US20020099169 Modulation of preferential transcription factor; obtain sample containing transcription factor, incubate with modulator, monitor transcriptional activity |
| 07/25/2002 | US20020099096 Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer |
| 07/25/2002 | US20020099014 Method for treatment of insulin resistance in obesity and diabetes |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098166 Genetically modified cells and their use in the prophylaxis or therapy of disorders |
| 07/25/2002 | DE10104327A1 New 11beta-halo-testosterone derivatives useful in male hormone replacement therapy and in male fertility control |
| 07/25/2002 | CA2435260A1 Receptors and membrane-associated proteins |
| 07/25/2002 | CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/24/2002 | EP1224322A2 Gene sequence variations with utility in determining the treatment of disease |
| 07/24/2002 | EP1224291A1 Multiple sclerosis-related superantigen |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224268A1 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224218A1 Dna encoding human alpha1g-c t-type calcium channel |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224204A1 Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11 |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |
| 07/24/2002 | EP1224187A2 Certain alkylene diamine-substituted heterocycles |
| 07/24/2002 | EP1223961A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 07/24/2002 | EP1223936A1 Oral formulations for anti-tumor compounds |
| 07/24/2002 | EP1223915A1 Dry powder compositions having improved dispersivity |
| 07/24/2002 | EP0835263B9 Somatostatin peptides |
| 07/24/2002 | CN1360590A Androgen glycosides and androgenic activity thereof |
| 07/24/2002 | CN1360589A Orally active androgens |
| 07/24/2002 | CN1360572A Vitamin D3 Analogs |
| 07/24/2002 | CN1087939C 碘酸钾制剂 Preparation of potassium iodate |
| 07/24/2002 | CN1087937C Medicine of inhibiting Alzheimer's disease |
| 07/23/2002 | US6423708 Aralkyl and aralkylidene heterocyclic lactams and imides |
| 07/23/2002 | US6423700 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same |
| 07/23/2002 | US6423686 LHRH antagonist peptides |
| 07/18/2002 | WO2002055693A2 Method for inhibiting the expression of a target gene |
| 07/18/2002 | WO2002055690A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/18/2002 | WO2002055688A2 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | WO2002055532A2 Variant growth hormone molecules conjugated with macromolecular compounds |
| 07/18/2002 | WO2002055531A1 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy |
| 07/18/2002 | WO2002055514A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 07/18/2002 | WO2002055510A1 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof |
| 07/18/2002 | WO2002055086A2 Hormone replacement therapy method and its administration form |
| 07/18/2002 | WO2002055012A2 Therapeutic heterocyclic compounds |
| 07/18/2002 | WO2002029088A3 Highly expressible genes |
| 07/18/2002 | WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002016310A9 Selective androgen receptor modulators and methods of use thereof |
| 07/18/2002 | WO2002013758A3 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 07/18/2002 | WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/18/2002 | WO2002007722A3 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 07/18/2002 | WO2002006242A3 5-substituted 2-aryl-4-pyrimidinones |
| 07/18/2002 | WO2002002633A3 Transporters and ion channels |
| 07/18/2002 | WO2001094391A3 Intracellular signaling proteins |
| 07/18/2002 | WO2001085783A3 Nucleic acids encoding polypeptides related to the alpha subunit of the glycoprotein hormone family and methods of use thereof |
| 07/18/2002 | WO2001081590A3 Protein phosphatases |
| 07/18/2002 | WO2001079468A3 Drug metabolizing enzymes |
| 07/18/2002 | WO2001079282A3 Molecules associated with human reproduction |
| 07/18/2002 | WO2000078972A9 Regulation with binding cassette transporter protein abc1 |
| 07/18/2002 | US20020095024 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 07/18/2002 | CA2434269A1 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | CA2434152A1 Therapeutic heterocyclic compounds |
| 07/18/2002 | CA2433656A1 Hormone replacement therapy method and its administration form |
| 07/18/2002 | CA2432350A1 Method for inhibiting the expression of a target gene |
| 07/17/2002 | EP1222925A2 Kavalactone as TNF-alpha production inhibitor |
| 07/17/2002 | EP1222226A1 Highly-neutralized ethylene copolymers and their use in golf balls |
| 07/17/2002 | EP1222209A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 07/17/2002 | EP1222188A1 Novel imidazopyridine carbonitrile compounds |
| 07/17/2002 | EP1222174A1 Imidazol-4-ylmethanols used as inhibitors of steroid c17-20 lyase |
| 07/17/2002 | EP1222170A1 Novel nicotinonitrile compounds |
| 07/17/2002 | EP1222169A1 Novel trisubstituted pyridine compounds |
| 07/17/2002 | EP1221973A1 CD40 antagonist for treating psoriasis |
| 07/17/2002 | EP1221942A1 Biodegradable microparticles with novel erythropoietin stimulating protein |
| 07/17/2002 | EP1221939A1 Ortho ester lipids |
| 07/17/2002 | EP1221865A2 Food supplement for increasing lean mass and strength |
| 07/17/2002 | CN1359293A Pharmaceutical compositions comprising dipeptidy peptidase in inhibitors for the promotion of growth |
| 07/16/2002 | US6420591 Carbamates and compositions thereof, and methods for their use for treating cancer, inflammation, or a viral infection |
| 07/16/2002 | US6420376 Amido spiropiperidines promote the release of growth hormone |
| 07/16/2002 | US6420353 Use of 7 α-substituted steroid to treat neuropsychiatric, immune or endocrine disorders |
| 07/11/2002 | WO2002054064A2 Method for screening for progesterone receptor isoform-specific ligands |
| 07/11/2002 | WO2002053565A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient |
| 07/11/2002 | WO2002053522A2 Novel estrogen receptor ligands and methods i |
| 07/11/2002 | WO2002053519A2 Hydrophobic polyamine analogs and methods for their use |
| 07/11/2002 | WO2002053110A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002053091A2 Medicinal combination of a biguanine (metformin) and arginine |
| 07/11/2002 | WO2002053090A2 Medicinal association of a biguanine (metformin) and arginine |
| 07/11/2002 | WO2001095890B1 Oral pharmaceutical compositions containing terbinafine |
| 07/11/2002 | WO2001046443A3 Proteases |
| 07/11/2002 | WO2001043540A3 Methods for producing transgenic animals |
| 07/11/2002 | WO2001021213A3 Inhibition of secretion from non-neuronal cells |
| 07/11/2002 | WO2001017568A3 Bioconjugation in vivo to pulmonary or blood components |
| 07/11/2002 | WO2000063438A3 Method of classifying a thyroid carcinoma using differential gene expression |
| 07/11/2002 | WO2000049937A9 Trpm-2 antisense therapy |
| 07/11/2002 | US20020091270 Sulfonamides containing oxazole and substituted thiophene rings, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure |
| 07/11/2002 | US20020091127 Semicarbazides and their uses |
| 07/11/2002 | US20020091105 Useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. |
| 07/11/2002 | US20020091104 Protein tyrosine phosphatases inhibitors, especially as antidiabetic agents |
| 07/11/2002 | US20020091078 Treating diabetes, especially Type II diabetes |
| 07/11/2002 | US20020090622 Detection of a polymorphism in a sodium transport protein; obtain sample, recover nucleotide sequences from sample, determine nucleotide sequences of sample, compare to control |
| 07/11/2002 | US20020090362 Immunotherapy using cytotoxic t lymphocytes (ctl) |